Curatis Holding AG (SWX:CURN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
24.90
-0.10 (-0.40%)
Apr 28, 2026, 5:30 PM CET
144.12%
Market Cap 128.85M
Revenue (ttm) 10.80M
Net Income (ttm) -1.42M
Shares Out 5.15M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE 1.49
Dividend n/a
Ex-Dividend Date n/a
Volume 1,960
Average Volume 3,006
Open 23.50
Previous Close 25.00
Day's Range 23.50 - 24.90
52-Week Range 9.72 - 27.90
Beta -1.06
RSI 66.93
Earnings Date Jun 15, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage... [Read more]

Sector Healthcare
Founded 2002
Employees 9
Stock Exchange SIX Swiss Exchange
Ticker Symbol CURN
Full Company Profile

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Financial Statements

News

There is no news available yet.